de Franchis R. Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63(3):743–52. https://www.ncbi.nlm.nih.gov/pubmed/26047908
Escorsell A, Pavel O, Cardenas A, Morillas R, Llop E, Villanueva C, et al. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: a multicenter randomized, controlled trial. Hepatology 2016;63(6):1957–67. https://www.ncbi.nlm.nih.gov/pubmed/26600191
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69(2):406–60. https://www.ncbi.nlm.nih.gov/pubmed/29653741
Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362(25):2370–9. https://www.ncbi.nlm.nih.gov/pubmed/20573925
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 2017;65(1):310–35. https://www.ncbi.nlm.nih.gov/pubmed/27786365
Hernandez-Gea V, Procopet B, Giraldez A, Amitrano L, Villanueva C, Thabut D, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology 2019;69(1):282–93. https://www.ncbi.nlm.nih.gov/pubmed/30014519
Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Balcar L, et al. Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis. Clin Gastroenterol Hepatol 2022. https://www.ncbi.nlm.nih.gov/pubmed/35842118
Pharmaco Australia Ltd. Dilatrend [product information]. Sydney: Pharmaco Australia Ltd; Amended January 2018, Accessed December 2019. https://www.tga.gov.au/
Seo YS, Park SY, Kim MY, Kim JH, Park JY, Yim HJ, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology 2014;60(3):954–63. https://www.ncbi.nlm.nih.gov/pubmed/24415445
Sharma M, Singh S, Desai V, Shah VH, Kamath PS, Murad MH, et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis. Hepatology 2019;69(4):1657–75. https://www.ncbi.nlm.nih.gov/pubmed/30125369
Stafylidou M, Paschos P, Katsoula A, Malandris K, Ioakim K, Bekiari E, et al. Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019;17(9):1744-55 e11. https://www.ncbi.nlm.nih.gov/pubmed/31077823
Symons K, Ermer J, editors. Australian injectable drugs handbook. 8th Melbourne: The Society of Hospital Pharmacists of Australia; 2020.
Szakacs Z, Eross B, Soos A, Matrai P, Szabo I, Petervari E, et al. Baveno Criteria safely identify patients with compensated advanced chronic liver disease who can avoid variceal screening endoscopy: a diagnostic test accuracy meta-analysis. Front Physiol 2019;10:1028. https://www.ncbi.nlm.nih.gov/pubmed/31481896
Tripathi D, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 2015;64(11):1680–704. https://www.ncbi.nlm.nih.gov/pubmed/25887380
Villanueva C, Albillos A, Genesca J, Garcia-Pagan JC, Calleja JL, Aracil C, et al. Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393(10181):1597–608. https://www.ncbi.nlm.nih.gov/pubmed/30910320
Villanueva C, Colomo A, Bosch A, Concepcion M, Hernandez-Gea V, Aracil C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368(1):11–21. https://www.ncbi.nlm.nih.gov/pubmed/23281973
Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, et al. Evidence-based recommendations to improve the safe use of drugs in patients with liver cirrhosis. Drug Saf 2018;41(6):603–13. https://www.ncbi.nlm.nih.gov/pubmed/29330714
Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev 2018;10:CD011510. https://www.ncbi.nlm.nih.gov/pubmed/30372514
